Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

In vivo alemtuzumab reduces the risk of graft-versus-host disease (GVHD) and nonrelapse mortality after reduced intensity allogeneic transplantation. However, it also delays immune reconstitution, leading to frequent infections and potential loss of graft-versus-tumor responses. Here, we tested the...

Full description

Bibliographic Details
Main Authors:	Chakraverty, R, Orti, G, Roughton, M, Shen, J, Fielding, A, Kottaridis, P, Milligan, D, Collin, M, Crawley, C, Johnson, P, Clark, A, Parker, A, Bloor, A, Pettengell, R, Snowden, J, Pettitt, A, Clark, R, Hale, G, Peggs, K, Thomson, K, Morris, E, Mackinnon, S
Format:	Journal article
Language:	English
Published:	2010

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Similar Items